Rua Bioscience

Rua Bioscience EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rua Bioscience (RUA.NZ) as of Oct 19, 2026 is -3.33 M NZD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.61 M NZD — a change of -27.72% (higher).

EBITDA

-3.33 MNZD

YoY

-27.72%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rua Bioscience is 2025 -3.33 M NZD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rua Bioscience was 2024 -4.61 M NZD. It decreases by -27.72% higher compared to the previous year.

The Rua Bioscience EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-2.04 M NZD
Jan 1, 2020
-3.62 M NZD
Jan 1, 2021
-6.28 M NZD
Jan 1, 2022
-7.58 M NZD
Jan 1, 2023
-11.99 M NZD
Jan 1, 2024
-4.61 M NZD
Jan 1, 2025
-3.33 M NZD
The Rua Bioscience EBITDA history
YEAREBITDAYoY
-3.33 MNZD-27.72%
-4.61 MNZD-61.53%
-11.99 MNZD+58.12%
-7.58 MNZD+20.73%
-6.28 MNZD+73.75%
-3.62 MNZD+77.61%
-2.04 MNZD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Rua Bioscience Stock analysis

What does Rua Bioscience do? Rua Bioscience Ltd, trading as RUA.NZ, is a pharmaceutical company headquartered in Gisborne, New Zealand. The company operates in the Health Care sector, specifically within Pharmaceuticals. It conducts research and development, and engages in pharmaceutical distribution and marketing. Rua Bioscience focuses on breeding, cultivating, manufacturing, and supplying medicinal cannabis products. The firm operates through one segment, offering research and development services and pharmaceutical products in Germany and New Zealand. It maintains a full research laboratory in Gisborne for cannabinoid testing, microscopic analysis, moisture analysis, sample preparation, extraction, solvent removal, viscosity measurements, and impurity testing. The company completed its IPO on October 22, 2020. Rua Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rua Bioscience stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rua Bioscience is -3.33 M NZD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Rua Bioscience changed from -4.61 M NZD to -3.33 M NZD, representing a -27.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Rua Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s NZD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Rua Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Rua Bioscience

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Rua Bioscience